Limited Stage Small Cell Lung Cancer Ls Sclc clinical trials

Explore recruiting limited stage small cell lung cancer ls sclc clinical trials.

Recruiting limited stage small cell lung cancer ls sclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Limited Stage Small Cell Lung Cancer Ls Sclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)

Austria, Portugal, Poland, France, Sweden, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Czechia, Austria, Spain, Germany, Netherlands, Latvia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Portugal, Hungary, France, Romania, Belgium, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Germany, Belgium, Italy, Spain, Netherlands, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

Italy, Romania, Germany, Belgium, Poland, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Limited Stage Small Cell Lung Cancer Ls Sclc trials by city

Limited Stage Small Cell Lung Cancer Ls Sclc in Toronto Limited Stage Small Cell Lung Cancer Ls Sclc in Vancouver Limited Stage Small Cell Lung Cancer Ls Sclc in Montreal Limited Stage Small Cell Lung Cancer Ls Sclc in Calgary Limited Stage Small Cell Lung Cancer Ls Sclc in Edmonton Limited Stage Small Cell Lung Cancer Ls Sclc in Ottawa Limited Stage Small Cell Lung Cancer Ls Sclc in Winnipeg Limited Stage Small Cell Lung Cancer Ls Sclc in Quebec City Limited Stage Small Cell Lung Cancer Ls Sclc in Hamilton Limited Stage Small Cell Lung Cancer Ls Sclc in Kitchener Limited Stage Small Cell Lung Cancer Ls Sclc in London Limited Stage Small Cell Lung Cancer Ls Sclc in Halifax Limited Stage Small Cell Lung Cancer Ls Sclc in New York Limited Stage Small Cell Lung Cancer Ls Sclc in Los Angeles Limited Stage Small Cell Lung Cancer Ls Sclc in Chicago Limited Stage Small Cell Lung Cancer Ls Sclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease